FDA
-
-
-
-
-
-
-
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) to Regain Global Rights to GAVRETO from Roche
-
-
-
-
-
-
-
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) Announces Positive Top-line Results from PIONEER Trial of AYVAKIT in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
-
-
-
-
-
-
-
Blueprint Medicines Reports First Quarter 2022 Results
-
-
-
-
-
-
-
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
-
-
-
-
-
-
-
Blueprint Medicines (BPMC) Confirms FDA Approves AYVAKIT for the Treatment of Adults with Advanced Systemic Mastocytosis
-
251,875 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All